Neuromodulation for Pain and Migraine

Get urgent help first

Some headaches are emergencies. The UK National Health Service lists these warning signs: a headache with a seizure, numbness or weakness in the body or face, a sudden and extremely painful onset, a recent head injury, or difficulty speaking, balancing, walking or remembering. [1] If you are in the United States and have any of these, call 911. A device is not a substitute for emergency care.

The short version

"Neuromodulation" here means devices that use electricity or magnetic pulses to change nerve activity in order to relieve pain. For migraine there are several wearable and handheld devices, each cleared by the FDA for specific uses. The evidence differs from device to device, so one device's results or clearance should not be applied to another. This page is information only, not medical advice. For labels, see how we label evidence.

What the FDA records say, device by device (read 2026-10-22)

Notes. These are examples I could read, not a complete list. Many later clearances and updated models exist, and I did not read their indications; the Nerivio name alone appears in several FDA records from 2020 to 2025. [3] The FDA classifies the device types too, for example transcranial magnetic stimulators for headache, external vagal nerve stimulators for headache, and trunk and limb stimulators to treat headache. [10][11][12] A type classification is not an approval of every product in it. For the gammaCore, the De Novo summary says safety and effectiveness were not established for acute treatment of chronic cluster headache and that it is not indicated for people with an active implanted device such as a pacemaker. [6]

What trials show for acute migraine

Remote electrical neuromodulation. A sham-controlled trial of 252 adults found pain relief at 2 hours in 66.7% with active stimulation versus 38.8% with sham. [13] A 2025 meta-analysis of 12 studies (9,912 people) pooled single-arm results, finding about 22% pain-free at 2 hours, and separately found an odds ratio of 2.77 for pain-free status in sham-controlled comparisons. [14] Single-arm results cannot separate the device effect from placebo response.

Noninvasive vagus nerve stimulation. In the PRESTO trial (248 people), pain freedom was higher than sham at 30 minutes (12.7% vs 4.2%) but the 2-hour primary endpoint did not reach statistical significance (30.4% vs 19.7%, p = 0.067). [15]

Single-pulse magnetic stimulation. In a trial of a portable single-pulse device in people with migraine with aura, 39% were pain-free at 2 hours with active stimulation versus 22% with sham (a 17-point gain). [16] This trial tested one device, so it does not by itself support other magnetic devices.

Overall. A 2021 JAMA review graded the certainty of benefit for pain as moderate for remote electrical neuromodulation and noninvasive vagus nerve stimulation and low for transcranial magnetic stimulation and external trigeminal stimulation. [17] A 2025 International Headache Society guideline issued only weak recommendations for four named devices in acute treatment and for three in prevention, with evidence rated very low to moderate and small sample sizes and design problems noted. [18] The abstracts I read do not state funders, which is worth checking in the full papers.

Regulatory versus guideline. The guideline's weak preventive recommendations named gammaCore Sapphire, Cefaly and Nerivio. [18] In the FDA records I read, the Nerivio De Novo summary said preventive use had not been demonstrated, and the gammaCore preventive indication I read is for cluster headache, not migraine. [2][5] Later clearances may differ, so check the exact indication on a device's FDA record.

Chronic pain beyond headache

• Repetitive magnetic stimulation of the brain's motor cortex: a European expert guideline (literature to the end of 2018) rated definite efficacy, its top level, for high-frequency stimulation over the primary motor cortex, on the side opposite the pain, for neuropathic pain. [19] It rated probable efficacy, its second level, for some fibromyalgia uses. [19] I did not verify an FDA clearance for neuropathic pain in the sources I read.
• Cranial electrical stimulation: evidence for pain is mixed to insufficient. See that page. [20]
• Neurofeedback: promising but limited. See neurofeedback. [21]
• Implanted spinal cord stimulators are not reviewed here.

Related guides

Acupuncture for migraine and headache, pain and headache-related research, device-specific approval for brain stimulation, vagus nerve stimulation and transcranial magnetic stimulation.